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Abstract
Human schistosomiasis—or bilharzia—is a parasitic disease caused by trematode flukes of the 
genus Schistosoma. By conservative estimates, at least 230 million people worldwide are infected 
with Schistosoma spp. Adult schistosome worms colonise human blood vessels for years, 
successfully evading the immune system while excreting hundreds to thousands of eggs daily, 
which must either leave the body in excreta or become trapped in nearby tissues. Trapped eggs 
induce a distinct immune-mediated granulomatous response that causes local and systemic 
pathological effects ranging from anaemia, growth stunting, impaired cognition, and decreased 
physical fitness, to organ-specific effects such as severe hepatosplenism, periportal fibrosis with 
portal hypertension, and urogenital inflammation and scarring. At present, preventive public 
health measures in endemic regions consist of treatment once every 1 or 2 years with the 
isoquinolinone drug, praziquantel, to suppress morbidity. In some locations, elimination of 
transmission is now the goal; however, more sensitive diagnostics are needed in both the field and 
clinics, and integrated environmental and health-care management will be needed to ensure 
elimination.
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Introduction
Schistosomiasis—also known as bilharzia—is an infectious disease that affects more than 
230 million people worldwide, according to conservative estimates.1,2 It is caused by 
trematode parasites of the genus Schistosoma;3 the adult male and female worms live within 
the veins of their human host, where they mate and produce fertilised eggs. The eggs are 
either shed into the environment through faeces or urine, or are retained in host tissues 
where they induce inflammation and then die. The eggs that reach freshwater will hatch, 
releasing free-living ciliated miracidia that then infect a suitable snail host. In the snail, the 
parasite undergoes asexual replication through mother and daughter sporocyst stages, 
eventually shedding tens of thousands of cercariae (the form infectious for human beings) 
into the water. The asexual portion of the lifecycle in the snail (figure 1) requires 4–6 weeks 
before infectious cercariae are released. After cercariae penetrate the skin of the mammalian 
host, the maturing larvae (schistosomula) need about 5–7 weeks before becoming adults and 
producing eggs. These intervals (in both the snail and human being) are termed prepatent 
periods, when the infection is ongoing but release of cercariae (from snails) or eggs (from 
humans) cannot be detected. Cercariae can remain infective in freshwater for 1–3 days, but 
deplete their energy reserves greatly over a few hours.4 Eggs—whether excreted or retained 
in the body—die within 1–2 weeks after being released by the female worm.
Three main species of schistosomes infect human beings, Schistosoma haematobium, 
Schistosoma mansoni, and Schistosoma japonicum. S haematobium and S mansoni both 
occur in Africa and the Middle East, whereas only S mansoni is present in the Americas. S 
japonicum is localised to Asia, primarily the Philippines and China. Three more locally 
distributed species also cause human disease: Schistosoma mekongi, in the Mekong River 
basin, and Schistosoma guineensis and Schistosoma intercalatum in west and central Africa 
(figure 2). Each species has a specific range of suitable snail hosts, so their distribution is 
defined by their host snails’ habitat range. S mansoni and S haematobium need certain 
species of aquatic freshwater Biomphalaria and Bulinus snails, respectively. S japonicum 
uses amphibious freshwater Oncomelania spp snails as its intermediate host.
Schistosomes live an average of 3–10 years, but in some cases as long as 40 years, in their 
human hosts.6,7 Adult male and female worms live much of this time in copula, the slender 
female fitted into the gynaecophoric canal of the male, where she produces eggs and he 
fertilises them (appendix). Adult worms digest erythrocytes and although most of their 
energy is obtained by glucose metabolism,8,9 egg production is dependent on fatty acid 
oxidation10—both glucose and fatty acids being derived from the host. They live within 
either the perivesicular (S haematobium) or mesenteric (S mansoni, S japonicum, and others) 
venules. Schistosomes have no anus and cannot excrete waste products, so they regurgitate 
waste into the bloodstream. Some of these expelled products are useful for blood-based and 
urine-based diagnostic assays. S japonicum and S mekongi are zoonoses that also infect a 
wide range of mammalian hosts, including dogs, pigs, and cattle, which greatly complicates 
control and elimination efforts. Although S mansoni can infect rodents and non-human 
primates, human beings are thought to be its predominant mammalian reservoir. 
Understanding the schistosome lifecycle (figure 1) and the parasite's movement between 
intermediate (snail) and definitive (mammalian) hosts is fundamental to the control and 
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elimination of human schistosomiasis. Environmental changes can either increase11 or 
decrease12 transmission. Changes in snail habitat and predators are crucial determinants of 
transmission, and prepatent periods can affect the efficacy of treatment regimens.13 
Effective treatment of people (such that their excreta do not contain eggs), the prevention of 
sewage contamination of freshwater, the elimination of intermediate host snails, and the 
prevention of human contact with water containing infected snails can help to prevent 
transmission.
Although still in its infancy, studies of schistosome genomics will prove crucial for 
identification of candidates for drug targets and prophylactic vaccines.14 Schistosome 
populations are very genetically heterogeneous15,16 and genomic characterisation of human 
schistosomes can be used to establish epidemiological patterns of transmission, including 
insights into interspecies hybridisation among some schistosome species. For example, in 
areas with high transmission of both S haematobium and the S bovis parasites of cattle, 
bidirectional introgressive hybridisation occurs, yielding schistosomes of mixed heritage in 
people and snails.17 The implications of these findings are unclear for human disease, but 
these populations of hybrid schistosomes could prove problematic if they can replace 
existing species and parasite strains or extend intermediate host ranges.
Epidemiology
In regions endemic for schistosomiasis the most prevalent form of the disease is chronic 
schistosomiasis, resulting from repeated exposure to infectious cercariae. In such settings, a 
child's initial infection often occurs by age 2 years with the burden of infection increasing in 
intensity during the next 10 years as new worms colonise the child's body. Typically, the 
highest prevalence and intensities of infection occur in young adolescents (figure 3), after 
which both intensity and prevalence of infection generally decrease in adulthood. However, 
high prevalence can persist among subpopulations of adults who have frequent contact with 
water during their daily activities—eg, laundry, bathing, fishing, washing cars. In endemic 
regions, serosurveys show that almost every long-term resident becomes infected with 
schistosomes at some point in their life. In regions with typical transmission patterns, 60–
80% of school-age children and 20–40% of adults can remain actively infected.
The frequency of schistosome infections among infants and young children is being 
increasingly recognised.20 This situation was overlooked, partly, because of an emphasis on 
school-aged children, the low parasite egg output at this age, and the low sensitivity of 
standard diagnostics. Early childhood infection undoubtedly has a substantial role in host 
immunomodulation and the establishment of chronic antischistosome-egg inflammation that 
contributes to pathological effects in endemic paediatric populations.21
Pathogenesis and morbidity
All evidence suggests that schistosome eggs, and not adult worms, induce the morbidity 
caused by schistosome infections.22 Many eggs are not excreted and become permanently 
lodged in the intestines or liver (for S mansoni, S japonicum, and S mekongi) or in the 
bladder and urogenital system (for S haematobium). There, the eggs induce a granulomatous 
host immune response largely characterised by lymphocytes (which mainly produce T-
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helper-2 cytokines; eg, interleukins 4, 5, and 13), eosinophils, and, alternatively, activated 
macrophages (figure 4).23,24 These granulomas contain egg proteolytic enzymes to prevent 
tissue necrosis, but the process of granuloma formation induces chronic inflammation that 
leads to the disease manifestations of schistosomiasis.25
Acute schistosomiasis occurs most often in travellers or immigrants to schistosome-endemic 
regions who are exposed to schistosome antigens for the first time at an older age than usual. 
It occurs weeks to months after infection, as a consequence of worm maturation, egg 
production, release of egg antigen, and the host's florid granulomatous and immune complex 
responses. Acute schistosomiasis is sometimes referred to as Katayama syndrome and the 
typical clinical presentation is a sudden onset of fever, malaise, myalgia, headache, 
eosinophilia, fatigue, and abdominal pain lasting 2–10 weeks. This aspect of schistosomiasis 
has been reviewed in detail.26 The limited presentation of this syndrome in residents of 
endemic regions is probably a result of in-utero priming of T-lymphocyte and B-lymphocyte 
responses of babies born to mothers with helminthic infections.27,28
Over time, the granulomatous response to eggs is downregulated through several 
mechanisms in most individuals, leading to progression to the chronic intestinal form of the 
disease for S mansoni, S japonicum, and S mekongi. This form of the disease presents as 
non-specific intermittent abdominal pain, diarrhoea, and rectal bleeding, with the frequency 
of symptoms often related to the intensity of infection.29 Such gastrointestinal features are 
often focal with isolated mucosal hyperplasia, pseudopolyposis, and polyposis interspersed 
with normal bowel (appendix).30 Some people with intestinal schistosomiasis only poorly 
immunoregulate their response to parasite egg antigens31 and consequently develop 
extensive fibrosis and subsequent hepatosplenic disease with periportal fibrosis.32 Patients 
with periportal fibrosis—also called Symmer's pipe-stem fibrosis—retain hepatocellular 
function,33 differentiating the disease from cirrhosis and other liver diseases. Clinical 
features include upper abdominal discomfort with palpable nodular and hard hepatomegaly, 
often with splenomegaly. Ascites and haematemesis from oesophageal varices as a 
complication of portal hypertension can rapidly lead to death.34 Substantial pulmonary 
hypertension caused by granulomatous pulmonary arteritis can also occur in patients with 
advanced hepatic fibrosis disease.35 The time from initial infection to advanced fibrosis is 
usually 5–15 years.36 However, periportal fibrosis can occur in children as young as 6 
years,37 showing the need for screening and treatment of preschool children.20
By contrast, the defining symptom for urogenital schistosomiasis (S haematobium) is 
haematuria, often presenting with urinary frequency, burning micturition, and suprapubic 
discomfort. In endemic regions, haematuria is so widespread that it is thought a natural sign 
of puberty for boys, and is confused with menses in girls.18 As with severe intestinal 
schistosomiasis, severe urogenital schistosomiasis results from poor immunoregulation of 
antischistosome-egg responses,38 leading to chronic fibrosis of the urinary tract presenting 
as obstructive uropathy (hydroureter and hydronephrosis39), which—along with resulting 
bacterial superinfection and renal dysfunction—can have lethal consequences. Squamous-
cell carcinoma of the bladder is also strongly associated with S haematobium infection.40 
This tumour is often multifocal, and in regions endemic for S haematobium, occurs at a 
younger age than do transitional-cell bladder carcinomas.
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Female genital schistosomiasis caused by S haematobium strongly affects women's 
reproductive health.41 Eggs in the vesical plexus migrate to the genital tract causing 
inflammatory lesions in the ovaries, fallopian tubes, cervix, vagina, and vulva. Lower genital 
tract sandy patches are pathognomonic for female genital schistosomiasis and are associated 
with neovascularisation and friable mucosa that can result in contact bleeding 
(appendix).41,42 Female genital schistosomiasis causes pain and has been associated with 
stress incontinence, infertility, and increased risk of abortion. Unfortunately, treatment 
might not resolve these advanced forms of genital tract damage and there is growing 
evidence that such lesions can increase transmission of HIV.43 For men, urogenital 
schistosomiasis can present with haematospermia, orchitis, prostatitis, dyspareunia, and 
oligospermia. These conditions resolve more readily after antischistosomal treatment than 
do those of female genital schistosomiasis.44,45 S mansoni and S japonicum rarely affect the 
genital tract.41
All Schistosoma species cause non-specific but disabling systemic morbidities including 
anaemia, malnutrition, and impaired childhood development,46 as a result of the effect of 
continued inflammation on normal growth, iron metabolism, physical fitness, and cognitive 
function.47–49 Most anaemia in patients with schistosomiasis is anaemia of inflammation, 
linked with blood loss (and high parasitic loads), that contributes to total-body iron 
deficiency.21,50,51 Anaemia of inflammation is caused by iron trapping within the body 
mediated by the hepatic hormone hepcidin, the release of which is stimulated by infection-
related production of the pro-inflammatory cytokine interleukin 6.52 As a downstream 
consequence of chronic anaemia, decreased aerobic capacity negatively affects physical 
work output in regions endemic for schistosomes.49,53 Reduced intellectual function scores 
and acute and chronic undernutrition in children are also significantly associated with 
schistosomiasis.47,48,54 Fortunately, these deficits lessen with treatment,54,55 although the 
effective window for preventive treatment is probably short.56,57
Ectopic deposition of schistosoma eggs can lead to unexpected morbidities. The most 
common involves migration of parasite or eggs to the CNS, with symptoms of spinal 
compression or encephalopathy. Cerebral schistosomiasis occurs most commonly during S 
japonicum infections. Clinical presentation includes symptoms of meningoencephalitis with 
pyrexia, headache, vomiting, blurred vision, and altered sensorium or Jacksonian epilepsy. 
Spinal cord involvement—more common with acute schistosomiasis—can present as acute 
transverse myelitis or subacute myeloradiculopathy, and can result in paralysis or lumbar 
and leg pain, with muscle weakness, sensory loss, and bladder incontinence.58
Comorbidities
Schistosomiasis often occurs alongside other infectious diseases, with a wide range of co-
infecting organisms. In addition to its direct morbidities, schistosomiasis can affect 
immunological and physiological relations between the host and co-infecting pathogens. 
Thus, better control of schistosomiasis could provide adjunctive benefits in such areas. The 
most compelling example might be the effect of schistosomiasis on susceptibility to HIV 
infection. Among women with female genital schistosomiasis, the inflammation, friability, 
and neovascularisation of the genital epithelial tissue can lead to a compromised physical 
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barrier to exposure to HIV through sexual activity. In population-based studies, female 
genital schistosomiasis has been associated with a three to four times increased risk of HIV 
infection.43,59,60 This effect is compounded by increased concentrations of CD4-positive 
cells in semen of men with high intensity S haematobium infection.61 Furthermore, during 
active schistosomiasis, CD4-positive cells express increased concentrations of HIV 
coreceptors, providing more targets for HIV infection.62 HIV-positive people who have 
delayed treatment for schistosomiasis have a more rapid increase of viral load and CD4 T-
cell loss than do those treated early for schistosomiasis.63 However, a randomised trial 
detected no significant effect of schistosome or other helminth infection on the length of 
time before patients with HIV became eligible for antiretroviral therapy.64 So far no studies 
have been done of paediatric HIV and schistosomiasis co-infection, in which perinatally 
acquired HIV infection would normally precede schistosomiasis.
Schistosomiasis could also alter immune responses to co-infecting pathogens, allergens, or 
vaccines. The immunoregulatory responses during schistosome infection could 
downregulate T-helper-1-type immune response associated with control of viral or 
protozoan infections, or interfere with immunisation. In one of the most studied co-
infections, schistosomiasis seems to modulate malaria but studies have yielded conflicting 
results. In some,65–67 malaria prevalence, anaemia, and pathological effects are higher in 
children with schistosomiasis than in children without schistosomiasis, whereas antimalarial 
immune responses are diminished. However, other studies report no, or even a protective 
effect of schistosome infection on malaria, accompanied by increased immune 
responses.68,69 Schistosome and malaria-related antigens can cross-react to a degree,70 
further complicating the situation. The particular schistosome species involved could have 
an important effect—perhaps S haematobium promotes protective responses whereas S 
mansoni increases susceptibility to malaria.65,69 This difference could be a result of whether 
malaria sporozoites pass through a liver micro-environment immunologically affected by S 
mansoni egg granulomas.
Diagnosis
The diagnostic standard for active schistosomiasis is viable eggs in urine (S haematobium), 
faeces (S japonicum, S mansoni), or tissue biopsies. At present, the presence of infecting 
schistosomes cannot be ruled out definitively because of the low sensitivity of standard urine 
and faecal examinations.71 Microscopic examination of polycarbonate filters for eggs in the 
urine, urine dipstick assays for heme,72,73 or the Kato-Katz faecal examination for 
schistosome eggs74 are recommended by WHO for mapping and field-based control of 
schistosomiasis. Molecular techniques to detect schistosome DNA in faecal specimens have 
greater sensitivity than does microscopy75 but they still suffer from sampling limitations 
because of the irregular distribution of eggs in the excreta. DNA detection for serum or urine 
is also being assessed.76,77 Serological assays have proven useful clinically78 for diagnosis 
by detection of antibodies against schistosomal antigens, especially for symptomatic 
travellers, but for people in regions endemic for schistosomiasis, serology is unable to 
discriminate between active infection and past exposure. Detection of circulating 
schistosomal antigen overcomes this difficulty, and a point-of-contact circulating cathodic 
antigen assay is commercially available (Rapid Medical Diagnostics, Pretoria, South 
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Africa). This lateral flow cassette assay works on urine and seems to be more sensitive than 
the Kato-Katz assay for mapping of S mansoni-endemic regions.79 Its use permits on-site 
mapping of S mansoni without stool collections.
Better diagnostic tests for schistosomiasis are still needed—both in the field and in the clinic
—and new technologies are being studied. For example, PET scans80 have been used 
experimentally to detect adult parasites in vivo and microfluidics now offer the potential to 
miniaturise both antibody and parasite antigen detection assays.81 In addition to the 
importance of diagnostic improvements for clinical diagnoses, such advances will also be 
essential for drug development, elimination programmes, and vaccine assessment, in which 
infection must be accurately monitored over time. For the present, the absence of a true gold 
standard for quantitative correlations to actual worm burden remains a significant challenge.
An important public health aspect of monitoring control and elimination programmes is 
detection of schistosome infections in the snail host. Snail xenodiagnosis enables the 
identification of environmental contamination during control and elimination programmes, 
whether through the use of so-called sentinel snails82 or wild caught snails. Fully patent 
snail infections are detected by inducing cercarial shedding and prepatent infections can be 
identified by histological examination of snail tissues and by molecular parasitological 
techniques such as PCR83 or loop-mediated isothermal amplification assays.84 Comparisons 
of molecular assays and shedding assays show that most schistosome-infected snails do not 
progress to patency.85
Treatment
Praziquantel is the drug of choice for schistosomiasis. It is effective against all Schistosoma 
species, but its mechanism of action is not clearly understood. For full efficacy it needs an 
effective host antibody response.86,87 Praziquantel acts against adult schistosome worms, 
but has poor activity against immature schistosome larvae. A standard dose of 40 mg/kg is 
thought effective for treatment of S haematobium and S mansoni and can safely be used in 
pregnancy after the first trimester. For S japonicum and S mekongi, the recommended dose 
is 60 mg/kg. A dose pole is used in the field to determine the number of tablets to use.88 For 
preschool children (generally, younger than age 5 years), a new dose pole extends below 94 
cm.89 However, cure rates among preschool children are low,90 perhaps because of incorrect 
extrapolation of adult dosing. Praziquantel tablets are large and taste bitter; and no readily 
available paediatric formulation exists.91 Therefore, treatment of young children involves 
crushing tablets in carriers such as orange juice. Common side-effects of praziquantel 
include abdominal pain, headache, dizziness, and transient passage of blood in stool. High-
burden infections correlate with high risk of side-effects, which peak about 2–4 h after drug 
intake and are self-limited.
Artemisinin derivatives (such as artemether and artesunate) were developed as antimalarial 
drugs but also kill immature larval forms of developing schistosomes.92 However, because 
the time of cercarial exposure is normally unknown, the drug's use is limited, except after 
common point-source exposures. In areas of continuous transmission, artemisinin 
derivatives could be used in conjunction with praziquantel to improve overall cure rates and 
infection control. Meta-analysis has shown two-times higher cure rates after treatment with a 
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combination of praziquantel and artemisinin compared with praziquantel monotherapy.93 
However, research of dosing, formulation, and drug interactions is needed before 
combination treatments will become standard. Also, the potential for induction of 
artemisinin-resistant malaria parasites should be considered before standard use of such 
combinations in regions endemic for malaria.
Oxamniquine—a tetrahydroquinolone compound—is effective against only S mansoni and 
is no longer readily available.94 As with praziquantel, it has few side-effects, although some 
reports of heightened seizure activity in patients with underlying epilepsy have been 
noted.95
Even after extensive use in many endemic countries, no clear evidence of praziquantel 
resistance exists. However, such resistance can be induced experimentally,96 thus the threat 
of emerging resistance caused by mass monotherapy remains. Because its mechanism of 
action is unknown, no test for praziquantel resistance exists except clinical failure. Although 
praziquantel-tolerant schistosomes have been reported,96,97 such strains have not become 
established in field settings. Determination of clinical resistance is confounded by 
praziquantel's inactivity on immature worms—eg, in areas of constant reinfection, 
praziquantel might effectively kill adult worms but immature worms would then develop 
and present as adults, implying drug failure.97 In such settings, repeated praziquantel 
treatment 3–6 weeks apart kills initially resistant juvenile worms and improves drug 
treatment.98
Immunology
Immune responses during schistosomiasis can be thought of in terms of three topics: 
immunopathogenesis, resistance to reinfection, and immunodiagnostics. All three are 
affected by the development and establishment of chronic infection in the presence of 
chronic antigenic exposure. Faced with multiple antibody and cellular immune responses, 
adult schistosome worms persist in the bloodstream for decades, seemingly impervious to 
attack from immune effector mechanisms. This immune evasion by adult schistosomes is a 
result of several mechanisms99 and leads to a stalemate: the worms thrive and the host 
survives. Indeed, morbidity seems to be associated with immunopathology against only eggs 
that remain trapped in tissues. That immune responses are essential for effective 
treatment86,87,100 and that many anti-worm and anti-egg antibody responses are detected by 
serodiagnostic assays shows that adult worm antigens are readily detected by the host 
immune system, although intact worms effectively evade immune attack.
The immunopathology and immunoregulation associated with morbidity of schistosomiasis 
has been studied extensively. However, the immune mechanisms related to resistance, to 
reinfection, or in response to candidate vaccines are much less defined. Although adult 
worms are refractory to immune attack, immature, developing worms (skin-stage and lung-
stage schistosomulae) are the probable targets of protective immunity.101 Whether a 
protective resistance to reinfection exists is subject to ongoing debate,102 but several lines of 
evidence suggest that such resistance does develop, albeit slowly.103–105 The feasibility of 
inducing protective immunity has been shown through immunisation of various 
experimental hosts with irradiated cercariae.106,107 Data from endemic populations 
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(appendix) suggest that age-associated decreases in infection result from development of 
antiparasite immunity, rather than reduced contact with water.108
Although the responsible antigens and host immune responses are not fully defined, 
resistance to reinfection is consistently associated with IgE antibodies against worm 
antigens,103 low concentrations of IgG4 antibodies to worm antigens, and high blood 
eosinophilia.104 Resistance to reinfection is partial, which means that sterile immunity either 
does not develop or is rare. Studies of resistance to reinfection in human beings suggest that 
worm death, whether natural or after treatment, leads to release of immunogens that 
stimulate these protective responses, which then react with antigens expressed by 
susceptible incoming, migrating schistosomulae.103 Treatment of schistosomiasis increases 
common correlates of resistance: eosinophilia, parasite-specific IgE, and interleukin 5 
production in response to worm antigens109–111 and repeated treatment and retreatment of 
reinfections can lead to longer intervals before reinfection, even accounting for similar 
exposure patterns in highly exposed patients.105 Nevertheless, despite substantial effort and 
successful vaccination of experimental and reservoir hosts,112 no clinical trials for a human 
vaccine to schistosomiasis have been successful.
Burden of disease
Official estimates113 of the prevalence of Schistosoma infection were based on insensitive 
egg-detection techniques, which substantially under-represent active infection.114–116 
Schistosomiasis initiated by infection in early life persists into adulthood, even after 
infection terminates.117 Thus, although more than 230 million people are thought to be 
actively infected with schistosomes,1 a similar number are in a post-infection stage but 
continue to have residual morbidity. As a result, the number of people with schistosomiasis 
(ie, infection-related disease) could be closer to 440 million.
Classic descriptions of schistosomiasis-related morbidity focus on the pathologies unique to 
schistosome infection: periportal fibrosis for intestinal schistosomiasis and bladder 
deformity and hydronephrosis for urogenital schistosomiasis. In fact, these morbidities are 
much less common (5–10% of cases) than the less obvious, but disabling complications of 
anaemia, growth stunting, cognitive impairment, and decreased aerobic capacity (figure 5). 
These morbidities are systemic, associated with continuous inflammation during the first 
decades of life as a child has multiple, recurrent schistosome infections.56,117–120 These 
disabling complications are particularly relevant in low-income countries, where they 
contribute to impaired physical performance and limited educational attainment—
disabilities that become irreversible if infection cannot be prevented or suppressed 
throughout childhood. Schistosomiasis does not occur in isolation. It is a disease of poverty 
that often occurs where other parasites are prevalent and food insecurity is common. Thus, 
fully determining the global attributable fraction of schistosomiasis toward these morbidities 
is difficult. However, schistosomiasis alone is clearly a sufficient cause of these morbidities 
in many endemic locations.121
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Mapping and surveillance
Implementation of population-based control programmes by WHO guidelines requires 
prevalence estimates, to decide where to use school-based versus community-based delivery 
of praziquantel. A crucial consideration for the effective integration of preventive 
chemotherapy for neglected tropical diseases is whether schistosoma infection overlaps with 
filariasis, onchocerciasis, intestinal worm infections, and trachoma,122 which are all targeted 
for control through preventive chemotherapy. Climate measures and digital topography 
linked with data from past population-based surveys can broadly predict where schistosome 
transmission is possible. But schistosome prevalence can be focal, resolving into a 
patchwork mosaic of high-prevalence, medium-prevalence, and low-prevalence villages 
across a permissive landscape.123,124 Therefore, random cluster sampling across district-
level administrative units can substantially overestimate or underestimate infection risk in 
individual communities and schools.125–127 Randomised subsampling could be improved by 
testing paired locations at various distances apart to estimate the controlling distance factor 
for autocorrelation of infection prevalence within a given region.128 However, because 
prevalence can vary significantly over 2–5 km, it might be best to briefly survey all intended 
treatment locations (implementation units) with rapid sampling techniques (limited to 15–50 
people per site). For initial allocation of S haematobium treatment, the WHO's Red Urine 
Group consortium showed that a prevalence of visible (gross) haematuria of 10% or greater 
effectively identifies high-prevalence communities.129 However, for S mansoni infection, 
symptom scores or occult blood testing—although indicative of severe disease130,131—are 
not sufficient to map levels of infection for preventive chemotherapy. Instead, Lot-Quality 
Assurance or Multiple Category Lot-Quality Assurance approaches are used for limited 
testing of a single stool to classify communities as having high or low prevalence.132 Point-
of-care urine assays might supplant stool testing for this crucial mapping and decision 
process.79 A shortcoming of rapid testing strategies is that test sensitivity will probably fall 
as programmes succeed and prevalence and intensity falls. More sensitive testing of more 
residents will be needed to define regions that still have high transmission and to establish if 
elimination has been achieved. For S haematobium infection, dipstick diagnosis of 
microscopic haematuria still seems to be adequate to detect low-level infection. However, 
for S mansoni and S japonicum new elimination diagnostic tests are needed.
Control and elimination
It is an exciting time for control and elimination of schistosomiasis. In 1984, the WHO 
endorsed a strategy to control morbidity caused by schistosomiasis through preventive 
chemotherapy with praziquantel.133 Because of its excellent tolerability and generally good 
ability to either cure or drastically reduce egg output (70–90%),134,135 praziquantel can be 
distributed yearly (or in alternate years) by moderately trained school teachers or community 
health workers to obtain sufficient coverage to control morbidity in children, even despite 
the possibility of reinfection, resulting in prevention of severe hepatosplenic or urogenital 
disease.73,115 WHO has recommended the inclusion of preschool children in preventive 
chemotherapy efforts.20,136
In 2012—through World Health Assembly Resolution 65.19—the WHO recommended that 
countries, if possible, aim beyond control of morbidity toward elimination of 
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schistosomiasis. This change of policy was a bold and important step. It is partly predicated 
on the pledge by Merck Serono (Geneva, Switzerland) to donate up to 250 million tablets of 
praziquantel per year137 and the demonstration by the Schistosomiasis Control Initiative, 
that nationwide rollout of preventive chemotherapy with praziquantel can be accomplished. 
The decision by a country to move towards elimination should not be made lightly. It must 
be based on years of extensive control and reliable prevalence mapping that justifies the 
decision. Countries will need diagnostic tests suitable for use in the field, suitable survey 
sampling schemes, and the human capacity to implement the necessary interventions. 
Meeting these requirements needs a strong platform of government commitment over a 
substantial period. After elimination, the programme must provide an adequately designed 
surveillance scheme based on sound epidemiological and statistical techniques and 
improved diagnostic instruments. Aside from drug donations, many countries will need 
international and binational assistance for implementation of elimination interventions.
Because preventive chemotherapy alone will not eliminate schistosomiasis from most 
regions, additional control measures should be integrated into national and regional 
programmes.138 For the first 60 years of large-scale efforts to control schistosomiasis, snail 
control was the primary method used to prevent infection because no drugs were suitable for 
mass distribution. Although chemicals, habitat change, predators, and biological competitors 
have been used to reduce snail populations, efforts at present primarily use the molluscicide 
niclosamide, which kills snails at low concentrations and is non-toxic to people. However, it 
is toxic to some freshwater fish and amphibians.139,140 Niclosamide is a licensed pesticide 
in the USA, and is widely used for control of snails141,142 and sea lampreys.143 When used 
properly in suitable habitats, it has been an important contributor to schistosomiasis 
elimination campaigns.144–146
Behavioural modification is a possible, but challenging, approach to management of any 
health problem. However, with proper community involvement, it could be useful for 
reduction of both exposure of people to schistosome-containing water and contamination of 
snail habitat by human excreta containing schistosome eggs. Behavioural modification—
without provision of feasible alternatives—is destined to fail, but in conjunction with 
improvements in water and sanitation, it could prove successful. Provision of schistosome-
safe water for washing, bathing, and recreation is effective but expensive.147
Ongoing studies of the Schistosomiasis Consortium for Operational Research and 
Evaluation in five African countries will help determine the regimens needed to gain and 
sustain control of morbidity. In Zanzibar, studies are underway to understand the thresholds 
and combined activities needed for elimination.148 Widespread elimination will almost 
certainly need integrated use of many or all the methods that can be applied: preventive 
chemotherapy, snail control, behavioural modification, water and sanitation improvements, 
and perhaps eventually a prophylactic or transmission-blocking vaccine.
The coordination and logistics needed at national, regional, and continental scales to reach 
sustained control of morbidity, then elimination, are daunting. Nevertheless, now is the time 
to move towards this goal. World Health Assembly resolution 65.21 calls on all countries to 
intensify interventions to control schistosomiasis and to strengthen surveillance of 
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schistosomiasis transmission. It also recommends that endemic countries embark on 
elimination programmes and develop means to document their progress. The resolution calls 
on WHO to report on progress towards elimination of schistosomiasis to the Executive 
Board and the World Health Assembly every 3 years.149 The ultimate vision is a world free 
of schistosomiasis, with the intermediate goals of controlling morbidity caused by 
schistosomiasis by 2020, eliminating schistosomiasis as a public health problem by 2025, 
and interrupting transmission of schistosomiasis in most regions and in selected countries in 
Africa by 2025.150
Conclusion
Schistosomiasis is an ancient human disease with effects worldwide, particularly in the 
poorest communities. Effective early treatment is possible, thereby preventing the 
substantial immune-mediated effects of Schistosoma infection on human health. New 
diagnostic tests and new approaches to treatment implementation are aimed at local, then 
regional elimination, thus changing the public health agenda from curative approaches to a 
truly preventive strategy.
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Search strategy and selection criteria
We did a systematic search of PubMed, Medline, Google Scholar, and Embase for 
relevant studies, with the wildcard search terms “schistosome*”, “bilharz*”, and related 
subject headings for reports published between Jan 1, 2006 and Dec 31, 2013. Selection 
of studies was not limited by language. Reports were independently reviewed for 
inclusion by at least two authors. Older references were included on the basis of their 
importance.
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Figure 1. Lifecycles of Schistosoma mansoni, Schistosoma haematobium, and Schistosoma 
japonicum
(A) Paired adult worms (larger male enfolding slender female). (B) Eggs (left to right, S 
haematobium, S mansoni, S japonicum). (C) Ciliated miracidium. (D) Intermediate host 
snails (left to right, Oncomelania, Biomphalaria, Bulinus). (E) Cercariae.
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Figure 2. Global distribution of countries where human schistosomiasis is transmitted
Adapted from Gryseels and colleagues.5
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Figure 3. Age-prevalence and age-intensity of infection curves for Schistosoma haematobium (A) 
and Schistosoma mansoni (B)
Data from King and colleagues18 and DeStigter and colleagues.19
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Figure 4. Schistosoma mansoni egg-induced granulomas in the liver of an infected mouse
Eggs are roughly 120–180 μm long, 45–70 μm wide.
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Figure 5. Effect of schistosomiasis on aerobic capacity in children in Kenya and Canada
Data taken from Bustinduy and colleagues.49
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